HYPERTENSIVE, HYPERVOLEMIC HEMODILUTIONAL THERAPY FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE - IS IT EFFICACIOUS - YES

Authors
ULLMAN JS BEDERSON JB
Citation
Js. Ullman et Jb. Bederson, HYPERTENSIVE, HYPERVOLEMIC HEMODILUTIONAL THERAPY FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE - IS IT EFFICACIOUS - YES, Critical care clinics, 12(3), 1996, pp. 697
Citations number
71
Categorie Soggetti
Emergency Medicine & Critical Care
Journal title
Critical care clinics → ACNP
ISSN journal
07490704
Volume
12
Issue
3
Year of publication
1996
Database
ISI
SICI code
0749-0704(1996)12:3<697:HHHTFA>2.0.ZU;2-F
Abstract
Vasospasm is an important contributor to death and disability after an eurysmal subarachnoid hemorrhage (SAH), with delayed ischemic deficits (DID) occurring in as much as 30% of patients with angiographic spasm . There is strong evidence that hypertensive, hypervolemic, hemodiluti onal (HHH) therapy reverses the signs of DID and that its prophylactic use reduces the incidence of DID and subsequent infarction. Improveme nt of outcome in even the poorest-grade patients has been demonstrated . Literature supporting the use of HHH therapy in aneurysmal SAH is re viewed.